Terms: = Gastric cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Treatment
13 results:
1. Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.
Yin X; Zhu W; Tang X; Yang G; Zhao X; Zhao K; Jiang L; Li X; Zhao H; Wang X; Yan Y; Xing L; Yu J; Meng X; Zhao H
BMC Cancer; 2024 Apr; 24(1):486. PubMed ID: 38632501
[TBL] [Abstract] [Full Text] [Related]
2. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract] [Full Text] [Related]
4. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Kushlinskii NE; Gershtein ES; Chang VL; Korotkova EA; Alferov AA; Kontorshchikov MM; Sokolov NY; Karamysheva EI; Ognerubov NA; Stilidi IS
Klin Lab Diagn; 2021 Mar; 66(3):139-146. PubMed ID: 33793112
[TBL] [Abstract] [Full Text] [Related]
6. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological Features, treatment Strategy, and Prognosis of Primary Non-Hodgkin's Lymphoma of the Duodenum: A SEER Database Analysis.
Zheng G; Wang Y; Zhao Y; Zheng Z
Can J Gastroenterol Hepatol; 2020; 2020():9327868. PubMed ID: 32399459
[TBL] [Abstract] [Full Text] [Related]
8. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
[TBL] [Abstract] [Full Text] [Related]
9. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and gastric cancer Treated With Immune Checkpoint Inhibitors.
Ando K; Hamada K; Watanabe M; Ohkuma R; Shida M; Onoue R; Kubota Y; Matsui H; Ishiguro T; Hirasawa Y; Ariizumi H; Tsurutani J; Yoshimura K; Tsunoda T; Kobayashi S; Wada S
Anticancer Res; 2019 Sep; 39(9):5195-5201. PubMed ID: 31519633
[TBL] [Abstract] [Full Text] [Related]
10. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
11. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract] [Full Text] [Related]
12. A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway.
Wang HJ; Liu Y; Fan LQ; Han CL; Jiang Y; Cheng SJ; Li Y
Acta Pharmacol Sin; 2013 Dec; 34(12):1535-44. PubMed ID: 24241351
[TBL] [Abstract] [Full Text] [Related]
13. Clinical implication of positive oral contrast computed tomography for the evaluation of postoperative leakage after gastrectomy for gastric cancer.
Kim YE; Lim JS; Hyung WJ; Lee SK; Choi JY; Noh SH; Kim MJ; Kim KW
J Comput Assist Tomogr; 2010 Jul; 34(4):537-42. PubMed ID: 20657221
[TBL] [Abstract] [Full Text] [Related]
